Baudax Bio Inc expected to post a loss of 18 cents a share - Earnings Preview

Baudax Bio

06/08/2021 15:18

* Baudax Bio Inc  BXRX.OQ   BXRX.O  is expected to show a rise
in quarterly revenue when it reports results on August 9
(estimated). 
* The Malvern, Pennsylvania-based company is expected to report 
 a 33.7% increase in revenue to $466.67 thousand from $349
thousand a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Baudax Bio Inc is for a
loss of 18 cents per share. For the same quarter last year, the
company reported a loss of $1.72 per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Baudax Bio Inc
is $2​, about 72% above​ its last closing price of $0.56. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.19       -0.19      -0.27     Missed  -39.7
 Dec. 31 2020  -0.60       -0.61      -0.55     Beat    9.3
 Sep. 30 2020  -0.84       -0.74      0.62      Beat    184.2​
 Jun. 30 2020  -0.73       -0.65      -1.72     Missed  -163.3
 Mar.          -1.75​      -1.79      -3.87     Missed  -116.6
 31​ 2020​                                              ​
 Dec. 31 2019  -0.94       -0.94      -0.78     Beat    16.7​
 This summary was machine generated August 6 at 14:18 GMT.  All
figures in US dollars unless otherwise stated